GRFS vs JHG Comparison

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Janus Henderson Group provides investment management services to retail intermediary (55% of managed assets), self-directed (22%) and institutional (23%) clients. At the end of March 2025, active equities (58%), fixed-income (24%), multiasset (14%) and alternative (4%) investment platforms constituted the company's $373 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (62%), with customers from Europe, the Middle East, Africa, and Latin America (28%) and the Asia-Pacific region (10%) accounting for the remainder.